Background: This is a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure Trial Registration No: NCT03521934 (clinicaltrials.gov) Link Sponsor: Sanofi Trial Status: Recruitment stopped Enrolling Centers: Worldwide: 384 centers Core Study Team Basel:

SOLOIST